# Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

> **NCT02722733** · PHASE3 · UNKNOWN · sponsor: **Maria Sklodowska-Curie National Research Institute of Oncology** · enrollment: 90 (estimated)

## Conditions studied

- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** G-CSF (filgrastim)
- **DRUG:** Cytosine arabinoside with G-CSF (filgrastim)

## Key facts

- **NCT ID:** NCT02722733
- **Lead sponsor:** Maria Sklodowska-Curie National Research Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2017-03
- **Final completion:** 2017-04
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2016-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722733, "Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02722733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*